OBR Daily Commentary

forumImage

Repurposed Antidepressant Could Be A New Treatment For Recurrent Prostate Cancer

(USC News) Mar 3, 2020 - A USC pilot study — the first clinical trial of this drug in cancer patients — reported lower prostate-specific antigen levels in more than half of the participants.

Read Article arrow

Dean Gesme, MD (Posted: March 03, 2020)

quotesThe repurposing of FDA approved drugs could offer a partial solution to the astronomically escalating costs of de novo drug development, I hope that all physicians involved in clinical trials will devote a part of their efforts to identifying efficacious existing agents that could also address the issue of financial toxicity produced as a result of de novo drug development.quotes

Add Comment 1 Comment
forumImage

CytoDyn Files for Breakthrough Therapy Designation with the FDA for the Use of Leronlimab for the Treatment of Metastatic Triple-Negative Breast Cancer

(CytoDyn) Jan 13, 2020 - CytoDyn Inc., a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the Company has filed for Breakthrough Therapy designation (BTD) with the U.S. Food and Drug Administration (FDA) for the use of leronlimab as an adjuvant therapy for the treatment of metastatic triple-negative breast cancer (mTNBC). The BTD filing is based on data from the first patient in the Company’s mTNBC Phase 1b/2 trial and an additional single-patient trial under an emergency investigational new drug (IND) protocol evaluating leronlimab for the treatment of HER2+ metastatic, stage 4, breast cancer (MBC).

Read Article arrow

Dean Gesme, MD (Posted: January 13, 2020)

quotesC-C Chemokine Receptors (CCR5 or CD195) are ubiquitous on immune cells and play a significant role in inflammatory disorders and cancer. Antibodies targeting CCR5 are a welcome addition to our antineoplastic armamentarium.quotes

Add Comment 1 Comment
forumImage

SABCS 2019 – AstraZeneca and Daiichi Join the Her2 Resistance

(Vantage) Dec 11, 2019 - New data confirms that trastuzumab deruxtecan has an exciting destiny, but the antibody-drug conjugate’s impressive efficacy in late-stage breast cancer comes at a price.

Read Article arrow

Dean Gesme, MD (Posted: December 12, 2019)

quotesExtremely impressive efficacy in heavily pretreated metastatic HER-2 + breast cancer but the presence of treatment related interstitial lung disease (ILD) is concerning given ILD deaths in over 2% of treated patients and 13.6% all grade ILD. Trials underway in NSCLC and colorectal cancers Will bear close scrutiny for ILD in those populations.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics Professo...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Steven Spielberg Family Chair in Hematology Oncology P...

member photo
Stephen M. Schleicher, M.D., MBA

Community Oncology, Medical Oncologist, OneOncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...